Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Veeva Systems (VEEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Veeva Systems — how do they compare? Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B), while Veeva Systems trades at $298.35 (market cap $48.14B). The key difference: Veeva Systems is far larger — about 5.7× Hinge Health Inc. Class A Common Stock's market cap, and Hinge Health Inc. Class A Common Stock is more actively traded (1,624,526 versus 1,239,885). Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Veeva Systems for 6 Days on average.
| HNGE | VEEV | |
|---|---|---|
Market Cap | $8.47B | $48.14B |
Volume | 1,624,526 | 1,239,885 |
Sector | Health | Technology |
52-Week High | $105.14 | $301.63 |
52-Week Low | $31.17 | $151.43 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.09B | $41.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Veeva Systems (VEEV) trades at $301.63, up 1.95% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 74.96% gross margins and consistent earnings beats, while expanding partnerships with IQVIA and Servier enhance growth prospects. Recent news highlights AI innovations and increasing adoption among biotech firms, supporting positive sentiment.
Outlook remains favorable with analyst consensus at Buy (67% rating) and $290.50 price target, though valuation multiples appear elevated. Key risks include market saturation concerns and potential volatility from RSI overbought signals. The stock's proximity to 52-week highs suggests continued investor confidence in Veeva's life sciences software leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Veeva Systems
Veeva Systems provides cloud software, data, and services for the life sciences industry. Its applications support functions across clinical research, regulatory operations, quality, safety, and commercial teams.
Read more on VEEV →
